68Ga-DOTATATE PET in neuroectodermal tumours: First experience

Win, Zarni; Al-Nahhas, Adil; Towey, David; Todd, Jeannie F; Rubello, Domenico; Lewington, Val; Gishen, P.

doi:10.1097/mnm.0b013e32808ea0b0

Cited by 68 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in our data, significantly more metastatic lesions with somatostatin receptor expression than glucose metabolism were detected, particularly in osseous metastases. The finding of such high detectability in metastatic lesions clearly demonstrates that somatostatin receptor expression could be link to more aggressive behaviour of tumours [23][24][25]. Furthermore, a recently published study also showed that a more Bcomplex relationship^exists, where matched somatostatin receptor expression and glucose metabolism lesions was seen in higher tumoural grade in NET [37].…”

Section: F-fdg Pet/ct Images Although 68mentioning

confidence: 86%

See 1 more Smart Citation

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Tan

Hussein²,

Saad

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Section: F-fdg Pet/ct Images Although 68mentioning

confidence: 86%

“…Although the diagnostic yield of 68 Ga-DOTA-peptides PET/CT in the detection of PCC/ PGL has been evaluated in several studies [23][24][25][26], its promising role in these tumours is still not largely accepted.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Tan

Hussein²,

Saad

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…68 Ga-DOTATATE PET/CT was recently introduced into PPGL imaging and has shown excellent results in the patient groups evaluated thus far, which mainly include those with sporadic and SDHBrelated metastatic PPGL as well as head and neck PGLs (13,(29)(30)(31)(32)(33)(34).…”

Section: Discussionmentioning

confidence: 99%

Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes

et al. 2017

View full text Add to dashboard Cite

Pheochromocytoma/paraganglioma (PPGL) syndromes associated with polycythemia have previously been described in association with mutations in the von Hippel-Lindau gene. Recently, mutations in the prolyl hydroxylase gene (PHD) 1 and 2 and in the hypoxiainducible factor 2 a (HIF2A) were also found to be associated with multiple and recurrent PPGL. Such patients also presented with PPGL and polycythemia, and later on, some presented with duodenal somatostatinoma. In additional patients presenting with PPGL and polycythemia, no further mutations have been discovered. Because the functional imaging signature of patients with PPGLpolycythemia syndromes is still unknown, and because these tumors (in most patients) are multiple, recurrent, and metastatic, the goal of our study was to assess the optimal imaging approach using 4 different PET radiopharmaceuticals and CT/MRI in these patients. Methods: Fourteen patients (10 women, 4 men) with confirmed PPGL and polycythemia prospectively underwent 68 Ga-DOTATATE (13 patients), 18 F-FDG (13 patients), 18 F-fluorodihydroxyphenylalanine ( 18 F-FDOPA) (14 patients), 18 F-fluorodopamine ( 18 F-FDA) (11 patients), and CT/MRI (14 patients). Detection rates of PPGL lesions were compared between all imaging studies and stratified between the underlying mutations. Results: 18 F-FDOPA and 18 F-FDA PET/CT showed similar combined lesion-based detection rates of 98.7% (95% confidence interval [CI], 92.7%-99.8%) and 98.3% (95% CI, 90.9%-99.7%), respectively. The detection rates for 68 Ga-DOTATATE (35.3%; 95% CI, 25.0%-47.2%), 18 F-FDG (42.3; 95% CI, 29.9%-55.8%), and CT/MRI (60.3%; 95% CI, 48.8%-70.7%) were significantly lower (P , 0.01), irrespective of the mutation status. Conclusion: 18 F-FDOPA and 18 F-FDA are superior to 18 F-FDG, 68 Ga-DOTATATE, and CT/MRI and should be the radiopharmaceuticals of choice in this rare group of patients.

show abstract

“…This result has been corroborated by a study in which 68 Ga-DOTA-TATE was used to assess malignant pheochromocytoma in comparison with CT and 123 I-MIBG in a small group of five patients, in whom SRS findings were positive for several lesions that had negative or low MIBG uptake (Figure 4) [55] .…”

Section: Tumorsmentioning

confidence: 57%

Exploring new frontiers in molecular imaging: Emergence of⁶⁸Ga PET/CT

Tan

Goh²

2010

WJR

View full text Add to dashboard Cite

Since US Food and Drug Administration approval of 18-fluorodeoxyglucose as a positron tracer, and the development of hybrid positron emission tomography/ computed tomography machines, there has been a great increase in clinical application and progress in the field of nuclear molecular imaging. However, not underestimating the value of 18 F, there are known limitations in the use of this cyclotron-produced positron tracer. We hence turn our focus to an emerging positron tracer, 68 Ga, and examine the advantages, current clinical uses and potential future applications of this radioisotope. THE DEVELOPMENT OF POSITRON EMISSION TOMOGRAPHYPositron emission tomography (PET) imaging is essentially a story of a technique in wait of a technology. Since the discovery of positron emission in 1933 by Thibaud and Joliot et al, and the subsequent report of the coincident nature of emissions by Klemperer and Beringer, it has in effect taken close to half a century for the full realization of PET imaging in mainstream medical practice [1] . The history of PET development is a fascinating look into the technological advances in molecular medicine, and the account of Terry Jones provides fascinating reading [1] . The first use of positron tracers was likely performed in the 1940s using 11 CO in animal models [2] , with its first possible use in humans performed in the 1950s at the Hammersmith Hospital in London, United Kingdom using 15 O2 in studies of lung ventilation [3] . This was followed by increasing use of positron tracers in the physiological assessment of lung function, which resulted in the installation of the world's first hospital-based cyclotron in 1955. Subsequently, development shifted into myocardial perfusion [4] , cerebral perfusion [5][6][7] , and of course, glucose metabolism [8][9][10][11] . This development in positron tracers mirrored the progress in positron imaging. In the 1970s, Massachusetts General Hospital developed, what was then, the most advanced coincidence positron camera system, with a spatial resolution of approximately 1 cm [12] . This was followed by developments predominantly in single photon emission computed tomography (SPECT) with work done by Kuhl, Budinger and Gullberg, and in 1974, there were reports of the development of a dedicated single-plane positron emission transaxial tomograph, which was the precursor to the current PET systems.These developments explain the slow implementation of PET into clinical practice, as synchronous developments in both tracer and detector technology were reWorld Journal of Radiology W J R

show abstract

68Ga-DOTATATE PET in neuroectodermal tumours: First experience

Cited by 68 publications

References 20 publications

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes

Exploring new frontiers in molecular imaging: Emergence of⁶⁸Ga PET/CT

Contact Info

Product

Resources

About

68Ga-DOTATATE PET in neuroectodermal tumours: First experience

Cited by 68 publications

References 20 publications

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes

Exploring new frontiers in molecular imaging: Emergence of68Ga PET/CT

Contact Info

Product

Resources

About

Exploring new frontiers in molecular imaging: Emergence of⁶⁸Ga PET/CT